Erythromycin, clarithromycin, and azithromycin: are the differences real?
- PMID: 8851453
- DOI: 10.1016/s0149-2918(96)80179-2
Erythromycin, clarithromycin, and azithromycin: are the differences real?
Abstract
Erythromycin, clarithromycin, and azithromycin are clinically effective for the treatment of common respiratory and skin/skin-structure infections. Erythromycin and azithromycin are also effective for treatment of nongonococcal urethritis and cervicitis due to Chlamydia trachomatis. Compared with erythromycin, clarithromycin and azithromycin offer improved tolerability. Clarithromycin, however, is more similar to erythromycin in pharmacokinetic measures such as half-life, tissue distribution, and drug interactions. Misunderstandings about differences among the macrolides (erythromycin and clarithromycin) and the azalide (azithromycin) in terms of pharmacokinetics and pharmacodynamics, spectrum of activity, safety, and cost are common. The uptake and release of these compounds by white blood cells and fibroblasts account for differences in tissue half-life, volume of distribution, intracellular:extracellular ratio, and in vivo potency. Although microbiologic studies reveal that gram-positive pathogens are equally susceptible to these agents, significantly more isolates of Haemophilus influenzae are susceptible to azithromycin than to erythromycin or clarithromycin. Concentrations achieved at the infection site and duration above the minimum inhibitory concentration are as important as in vitro activity in determining in vivo activity against bacterial pathogens. Analysis of safety data indicates differences among these agents in drug interactions and use in pregnancy. Analysis of safety data reveals pharmacokinetic drug interactions for erythromycin and clarithromycin with theophylline, terfenadine, and carbamazepine that are not found with azithromycin. Both erythromycin and azithromycin are pregnancy category B drugs; clarithromycin is a category C drug. The numerous differences in pharmacokinetics, microbiology, safety, and costs among erythromycin, clarithromycin, and azithromycin can be used in the judicious selection of treatment for indicated infections.
Similar articles
-
History of macrolide use in pediatrics.Pediatr Infect Dis J. 1997 Apr;16(4):427-31. doi: 10.1097/00006454-199704000-00025. Pediatr Infect Dis J. 1997. PMID: 9109154 Review.
-
The macrolides: erythromycin, clarithromycin, and azithromycin.Mayo Clin Proc. 1999 Jun;74(6):613-34. doi: 10.4065/74.6.613. Mayo Clin Proc. 1999. PMID: 10377939 Review.
-
Microbiologic activity of the newer macrolide antibiotics.Pediatr Infect Dis J. 1997 Apr;16(4):432-7. doi: 10.1097/00006454-199704000-00026. Pediatr Infect Dis J. 1997. PMID: 9109155 Review.
-
Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients.Drug Saf. 1999 Jan;20(1):25-41. doi: 10.2165/00002018-199920010-00004. Drug Saf. 1999. PMID: 9935275 Review.
-
Dirithromycin: a new macrolide.Ann Pharmacother. 1996 Oct;30(10):1141-9. doi: 10.1177/106002809603001014. Ann Pharmacother. 1996. PMID: 8893122 Review.
Cited by
-
Repurposing of antibiotics for clinical management of COVID-19: a narrative review.Ann Clin Microbiol Antimicrob. 2021 May 21;20(1):37. doi: 10.1186/s12941-021-00444-9. Ann Clin Microbiol Antimicrob. 2021. PMID: 34020659 Free PMC article. Review.
-
Treating common ear problems in pregnancy: what is safe?Eur Arch Otorhinolaryngol. 2008 Feb;265(2):139-45. doi: 10.1007/s00405-007-0534-3. Epub 2007 Nov 23. Eur Arch Otorhinolaryngol. 2008. PMID: 18034353 Review.
-
Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.Clin Pharmacokinet. 1997 Feb;32(2):132-44. doi: 10.2165/00003088-199732020-00004. Clin Pharmacokinet. 1997. PMID: 9068928 Review.
-
Current Status of the Spectrum and Therapeutics of Helicobacter pylori-Negative Mucosa-Associated Lymphoid Tissue Lymphoma.Cancers (Basel). 2022 Feb 16;14(4):1005. doi: 10.3390/cancers14041005. Cancers (Basel). 2022. PMID: 35205754 Free PMC article. Review.
-
Discovery of Anti-Amoebic Inhibitors from Screening the MMV Pandemic Response Box on Balamuthia mandrillaris, Naegleria fowleri, and Acanthamoeba castellanii.Pathogens. 2020 Jun 16;9(6):476. doi: 10.3390/pathogens9060476. Pathogens. 2020. PMID: 32560115 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical